• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

In order to ensure your "Under Consideration" USAN domain name is available, USAN applicants should consider purchasing the .com, .net, and .org domain names of your USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following list of names for the drugs described are "under consideration" by the USAN Council:

March 2015

inotersen treatment of transthyretin-mediated amyloidosis
itacitinib treatment of psoriasis, arthritis, solid tumors
onvelcitinib treatment of psoriasis, arthritis, solid tumors
myoinositol treatment of Retinopathy of Prematurity (ROP)
parmetinostat treatment of early stage cutaneous T-cell lymphoma

February 2015

There are no applicable "names under consideration"

January 2015

alcanezumab treatment of migraine
andepatuzumab mafodotin treatment of cancer
cibinetide reduction in neuropathic pain
clecinimod treatment of chronic inflammatory disorders
domagrozumab treatment of Duchenne muscular dystrophy
dulosurad chronic management of hyperuricemia in patients with gout
ermenkumab cachexia, oncology, vascular disease, type 2 diabetes
ferric pyrophosphate citrate prevention and treatment of iron deficiency
ifriceptogene obladenovec antineoplastic
lanadelumab prevention of angioedemia in patients with hereditary angioedema
lorclatinib antineoplastic
mozanatinib treatment of cancer
pegapamodutide treatment of diabetes/obesity
prexasertib treatment of advance cancer
rarenlizumab treatment of cancer
raxatrigine treatment of neuropathic pain
rosomidna antineoplastic
sespribuvir treatment of hepatitis C
soromidna antineoplastic
tagutuzumab treatment of CD19 positive hematologic malignancies
vadadustat treatment of anemia associated with kidney disease
zoliflodacin antibacterial